IMS aims to contribute to the identification of new treatments for cancer and other diseases by promoting collaboration with RIKEN Program for Drug Discovery and Medical Technology Platforms (DMP). The DMP was founded in RIKEN in 2010 in order to support all phases of development of new therapeutics, from the discovery of promising targets to the identification of potential lead compounds such as small molecules and antibodies, and the acquisition of intellectual property rights to drugs and technologies that can then be brought to the development phase. The implementation of drug discovery requires different technology, thus DMP established several medical technology platforms that promote research and development. IMS contributes to this effort in several ways, including by setting up a facility for development of antibody drugs (Drug Discovery Antibody Platform Unit lead by Toshitada Takemori).

IMS now has five programs in association with DMP, including cancer treatment with NKT cells (Masaru Taniguchi), allergy prophylaxis (Masaru Taniguchi), Artificial adjuvant vector cells (Shin-ichiro Fujii), Leukemia treatment drugs targeting leukemic stem cells (Fumihiko Ishikawa), and a Mucosal Vaccine delivery System (Hiroshi Ohno). Some of programs will provide the transfer of potential drug candidates to pre-clinical and clinical phases of drug development.